Ido Weinberg, MD

Vitamin K antagonists have been extensively used as the standard of care in the treatment of venous thromboembolism for the past 60 years. The known limitations of vitamin K antagonists have been widely recognized; thus, alternatives have been sought after for decades.

From an efficacy standpoint, full-dose edoxaban has been found to be noninferior to warfarin in patients with nonvalvular atrial fibrillation and acute VTE.

Vitamin K antagonists have been extensively used as the standard of care in the treatment of venous thromboembolism for the past 60 years. The known limitations of vitamin K antagonists have been widely recognized; thus, alternatives have been sought after for decades.